MicroProbe deal

MPRO entered an agreement with Procter & Gamble to evaluate the clinical efficacy of MPRO’s DNA probe-based diagnostic tests for periodontal disease. The companies will conduct clinical efficacy studies and seek regulatory clearance of MPRO’s Affirm DP Microbial Identification Test System. Procter & Gamble has first option on a licensing agreement for exclusive distribution in the U.S. and Canada. MPRO markets Affirm in 11 countries outside the U.S. ...